Pre-close Trading Update

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to announce that trading during the last few months of the 2009 financial year remained strong.  As a result, the Company expects to report turnover for the full year to 31 December 2009 of approximately £31 million, an increase of approximately 42% on the previous year.

The Company has previously reported that it is restricting investment in development projects to very modest levels and therefore does not propose to continue with clinical trials of Isprelor^®, for the induction of labour, without third-party support.  In light of this, the carrying value of Isprelor^® on the Company’s balance sheet will be assessed as part of the year end procedures to see whether any impairment should be recognised.  Prior to any impairment charges, the book value of Isprelor^® development costs at 31 December 2009 was £2.8 million.

Excluding any impairment charges for Isprelor^®, results for the year to 31 December 2009 are expected to significantly exceed current market expectations, with pre-tax trading profits expected to be no less than £8.5 million. 

Alliance Pharma’s preliminary results for the 12 months to 31 December 2009 are scheduled to be released on 24 March 2010.

For further information:

Alliance Pharma plc            + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk

Buchanan Communications        + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic / Jennie Spivey

Numis Securities Limited       + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Brent Nabb,
Corporate Broking: David Poutney / James Serjeant